SciClone Pharmaceuticals, Inc.

SciClone Pharmaceuticals, Inc. is a global specialty biopharmaceutical company that develops and commercializes novel medicines for treating a broad range of the world's most serious diseases.
We believe the significance, prevalence and diversity of our disease targets, and the known limitations of current treatment alternatives, have created a compelling need for improved therapies, with novel medicines often enjoying premium pricing and rapid market acceptance. Our current product development and commercial activities are focused on this large, unmet market need.
Specifically, we have focused our current product development and commercial activities on the following diseases: hepatitis C, an infectious disease affecting 170 million people worldwide; hepatitis B, an infectious disease affecting 350 million people worldwide; the most common and deadliest form of liver cancer worldwide, hepatocellular carcinoma; the deadliest form of skin cancer and one of the most rapidly increasing types of cancer worldwide, malignant melanoma; HIV, the virus that causes AIDS; drug-resistant tuberculosis, an infectious disease reaching pandemic proportions worldwide; and cystic fibrosis, the most common fatal genetic disease among Caucasians.
Our flagship drug is ZADAXIN®, an immunotherapy. ZADAXIN boosts the body's immune system in its fight against multiple types of cancer and infectious diseases.
In the United States, Europe and Japan, the world's largest pharmaceutical markets, ZADAXIN is in, or is expected to enter, phase 2 and phase 3 development targeting five diseases: hepatitis C, hepatitis B, hepatocellular carcinoma, malignant melanoma.

Activity:

- Manufacturing
- Research & Development

Product / Technology type(s) covered:

- Bio
- Pharmaceuticals / Therapeutics

Therapeutic targets:

- AIDS
- Cancer
- Dermatology
- Infectious Diseases

Markets Covered

a. HeadQuarter:

b. Continent(s) active: North America , Europe , Asia

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: